Sex Difference in Bleeding Risk With P2Y12 Inhibitor Agents After Percutaneous Coronary Intervention [0.03%]
经皮冠状动脉介入治疗后P2Y12受体抑制剂的出血风险性别差异
Po-Wei Chen,Cheng-Han Lee,Ping-Yen Liu
Po-Wei Chen
Potential Role and Limitations of Estimated Glomerular Filtration Rate Slope Assessment in Cardiovascular Trials: A Review [0.03%]
估算肾小球滤过率斜率在心血管试验中的潜在作用和局限性：综述
Muhammad Shahzeb Khan,George L Bakris,Izza Shahid et al.
Muhammad Shahzeb Khan et al.
Importance: Cardiovascular trials have traditionally been underpowered to assess advanced chronic kidney disease (CKD) outcomes, and when included as a secondary end point, trials have used progression of CKD as incidence...
Fatima Rodriguez,Ashish Sarraju,Mintu P Turakhia
Fatima Rodriguez
Philip Huston Hutchens
Philip Huston Hutchens
Peter J Kennel,Hannah Rosenblum,Kelly M Axsom et al.
Peter J Kennel et al.
Importance: Heart failure (HF) is often characterized by an insidious disease course leading to frequent rehospitalizations and a high use of ambulatory care. Remote cardiac monitoring is a promising approach to detect wo...
Harry A Conte,Sok-Ja Janket,Eleftherios P Diamandis
Harry A Conte
Lifestyle Modification Is Appropriate as Primary Prevention-Reply [0.03%]
生活方式改变可作为一级预防措施——回复_letters和comments中的观点类标题
Romit Bhattacharya,Pradeep Natarajan
Romit Bhattacharya
Differences in Cardiovascular Risk, Coronary Artery Disease, and Cardiac Events Between Black and White Individuals Enrolled in the PROMISE Trial [0.03%]
PROMISE试验中纳入的黑人和白人心血管风险、冠状动脉疾病及心脏事件差异研究
Lili Zhang,Devvora Olalere,Thomas Mayrhofer et al.
Lili Zhang et al.
Importance: Race and ethnicity have been studied as risk factors in cardiovascular disease. How risk factors, epicardial coronary artery disease, and cardiac events differ between Black and White individuals undergoing no...
Observational Study
JAMA cardiology. 2022 Mar 1;7(3):259-267. DOI:10.1001/jamacardio.2021.5340 2022
Quentin R Youmans,Sanjiv J Shah,Sadiya S Khan
Quentin R Youmans
Nana Hiraki,Toshikazu D Tanaka,Michihiro Yoshimura
Nana Hiraki